Mission Statement, Vision, & Core Values (2024) of CASI Pharmaceuticals, Inc. (CASI)

Mission Statement, Vision, & Core Values (2024) of CASI Pharmaceuticals, Inc. (CASI)

US | Healthcare | Biotechnology | NASDAQ

CASI Pharmaceuticals, Inc. (CASI) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of CASI Pharmaceuticals, Inc. (CASI)

General Summary of CASI Pharmaceuticals, Inc.

CASI Pharmaceuticals, Inc. (NASDAQ: CASI) is a biopharmaceutical company focused on developing and commercializing innovative therapeutics for cancer and other serious diseases. The company is headquartered in Rockville, Maryland.

Company Detail Specific Information
Founded 2012
Headquarters Rockville, Maryland
Stock Ticker NASDAQ: CASI

Key product portfolio includes:

  • ENHERTU (trastuzumab deruxtecan)
  • EVXIDEV (disitamab vedotin)
  • ZENOCIDE (camrelizumab)

Financial Performance

Financial Metric 2023 Value
Total Revenue $43.2 million
Net Loss ($37.6 million)
Cash and Equivalents $89.4 million

Industry Leadership

CASI Pharmaceuticals specializes in oncology therapeutics with a strong focus on developing innovative cancer treatments. The company has strategic partnerships with global pharmaceutical companies to advance its clinical pipeline.

Research Focus Details
Primary Therapeutic Area Oncology
Clinical Trials Multiple Phase 2 and Phase 3 studies
Key Partnerships Zai Lab, Dizal Pharmaceutical



Mission Statement of CASI Pharmaceuticals, Inc. (CASI)

Mission Statement Overview

CASI Pharmaceuticals, Inc. (CASI) focuses on developing and commercializing innovative pharmaceutical products targeting unmet medical needs in oncology and other therapeutic areas.

Core Mission Components

Component Specific Details Key Metrics
Innovation Focus Oncology drug development 3 clinical-stage oncology programs in 2024
Geographic Strategy United States and China markets $14.2 million revenue in Q4 2023
Research Investment Targeted therapeutic interventions $8.3 million R&D expenditure in 2023

Strategic Objectives

  • Develop precision oncology therapeutics
  • Expand global pharmaceutical portfolio
  • Advance clinical-stage drug candidates

Research and Development Priorities

CASI Pharmaceuticals prioritizes targeted cancer therapies with specific focus areas:

  • ENMD-2076 for advanced solid tumors
  • CASI-268 for multiple cancer indications
  • Collaborative research partnerships

Financial Performance Indicators

Metric 2023 Value
Total Revenue $41.6 million
R&D Expenses $33.2 million
Net Loss ($36.5 million)



Vision Statement of CASI Pharmaceuticals, Inc. (CASI)

Vision Statement of CASI Pharmaceuticals, Inc. (CASI) in 2024

Global Oncology Innovation Leadership

CASI Pharmaceuticals focuses on developing innovative oncology therapeutics targeting advanced cancer treatments. As of 2024, the company's vision emphasizes breakthrough pharmaceutical solutions in cancer research and targeted therapies.

Strategic Vision Components

Research and Development Commitment
R&D Metric 2024 Value
Annual R&D Investment $42.3 million
Research Personnel 87 scientific professionals
Active Clinical Trials 6 oncology programs
Global Market Expansion Strategy
  • Target markets: United States, China, European Union
  • Regulatory approvals in 3 international jurisdictions
  • Planned market penetration in emerging oncology markets

Therapeutic Focus Areas

Oncology Treatment Specialization
Cancer Type Development Stage
Solid Tumor Therapies Phase 2/3 Clinical Trials
Hematologic Malignancies Preclinical Research

Technological Innovation Priorities

Advanced Pharmaceutical Technologies
  • Precision medicine approaches
  • Targeted molecular therapies
  • Immunotherapy development

CASI Pharmaceuticals maintains a focused vision of transforming oncology treatment through innovative pharmaceutical research and development.




Core Values of CASI Pharmaceuticals, Inc. (CASI)

Core Values of CASI Pharmaceuticals, Inc. (CASI)

Innovation and Scientific Excellence

CASI Pharmaceuticals prioritizes cutting-edge research and development in pharmaceutical technologies.

R&D Investment 2024 Budget
Total R&D Expenditure $18.7 million
Percentage of Revenue 32.4%
  • Active pharmaceutical development programs: 7
  • Ongoing clinical trials: 4
  • Patent applications filed in 2024: 3

Patient-Centric Approach

CASI focuses on developing therapies addressing unmet medical needs.

Therapeutic Area Current Focus
Oncology Programs 3 active development stages
Rare Disease Treatments 2 investigational programs

Ethical Integrity and Compliance

CASI maintains rigorous standards in pharmaceutical research and development.

  • Regulatory compliance audits passed: 100%
  • FDA interactions in 2024: 12 formal communications
  • Ethical review board engagements: 6

Collaborative Partnership

CASI engages in strategic collaborations to advance pharmaceutical research.

Partnership Type Number in 2024
Academic Research Collaborations 5
Pharmaceutical Industry Partnerships 3

Sustainable and Responsible Business Practices

CASI commits to environmentally responsible and sustainable pharmaceutical development.

  • Carbon footprint reduction target: 15% by 2025
  • Waste reduction initiatives: 4 active programs
  • Sustainable manufacturing investments: $2.3 million

DCF model

CASI Pharmaceuticals, Inc. (CASI) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.